Efficacy and safety of parecoxib in the treatment of acute renal colic: a randomized clinical trial

Detalhes bibliográficos
Autor(a) principal: Glina,Sidney
Data de Publicação: 2011
Outros Autores: Damiao,Ronaldo, Afif-Abdo,Joao, Maria,Carlos Francisco Santa, Novoa,Raúl, Cairoli,Carlos Eurico Dornelles, Wajsbrot,Dalia, Araya,Gaston
Tipo de documento: Artigo
Idioma: eng
Título da fonte: International Braz J Urol (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382011000600003
Resumo: PURPOSE: Although nonselective nonsteroidal anti-inflammatory drugs (nsNSAIDs) and opioids are effective treatments for acute renal colic, they are associated with adverse events (AEs). As cyclooxygenase-2 selective NSAIDs may provide a safer alternative, we compared the efficacy and safety of parecoxib versus an nsNSAID in subjects with acute renal colic. MATERIALS AND METHODS: Phase IV., multicenter, double-blind, noninferiority, active-controlled study: 338 subjects with acute renal colic were randomized to parecoxib 40 mg i.v. plus placebo (n = 174) or ketoprofen 100 mg IV plus placebo (n = 164). 338 subjects with acute renal colic were randomized to parecoxib 40 mg IV (n = 174) or ketoprofen 100 mg IV(n = 164) plus placebo. Subjects were evaluated 15, 30, 45, 60, 90 and 120 minutes after treatment start and 24 hours after discharge. Primary endpoint was the mean pain intensity difference (PID) at 30 minutes by visual analog scale (VAS) (per-protocol population). An ANCOVA model was used with treatment group, country, and baseline score as covariates. Non-inferiority of parecoxib to ketoprofen was declared if the lower bound of the 95% confidence interval (CI) for the difference between the two groups excluded the pre-established margin of 10 mm for the primary endpoint. RESULTS: Baseline demographics were similar. The mean (SD) mPID30 min was 33.84 (24.61) and 35.16 (26.01) for parecoxib and ketoprofen, respectively. For treatment difference (parecoxib-ketoprofen) the lower bound of the 95% CI was 6.53. The mean change from baseline in VAS 30 minutes after study medication was ~43 mm; AEs were comparable between treatments. CONCLUSIONS: Parecoxib is as effective as ketoprofen in the treatment of pain due to acute renal colic, is well tolerated, and has a comparable safety profile.
id SBU-1_f04c0c2f5c4b07303df83594ada7db37
oai_identifier_str oai:scielo:S1677-55382011000600003
network_acronym_str SBU-1
network_name_str International Braz J Urol (Online)
repository_id_str
spelling Efficacy and safety of parecoxib in the treatment of acute renal colic: a randomized clinical trialparecoxibketoprofenrenal coliclithiasispainanalgesiaCOX-2 selectivePURPOSE: Although nonselective nonsteroidal anti-inflammatory drugs (nsNSAIDs) and opioids are effective treatments for acute renal colic, they are associated with adverse events (AEs). As cyclooxygenase-2 selective NSAIDs may provide a safer alternative, we compared the efficacy and safety of parecoxib versus an nsNSAID in subjects with acute renal colic. MATERIALS AND METHODS: Phase IV., multicenter, double-blind, noninferiority, active-controlled study: 338 subjects with acute renal colic were randomized to parecoxib 40 mg i.v. plus placebo (n = 174) or ketoprofen 100 mg IV plus placebo (n = 164). 338 subjects with acute renal colic were randomized to parecoxib 40 mg IV (n = 174) or ketoprofen 100 mg IV(n = 164) plus placebo. Subjects were evaluated 15, 30, 45, 60, 90 and 120 minutes after treatment start and 24 hours after discharge. Primary endpoint was the mean pain intensity difference (PID) at 30 minutes by visual analog scale (VAS) (per-protocol population). An ANCOVA model was used with treatment group, country, and baseline score as covariates. Non-inferiority of parecoxib to ketoprofen was declared if the lower bound of the 95% confidence interval (CI) for the difference between the two groups excluded the pre-established margin of 10 mm for the primary endpoint. RESULTS: Baseline demographics were similar. The mean (SD) mPID30 min was 33.84 (24.61) and 35.16 (26.01) for parecoxib and ketoprofen, respectively. For treatment difference (parecoxib-ketoprofen) the lower bound of the 95% CI was 6.53. The mean change from baseline in VAS 30 minutes after study medication was ~43 mm; AEs were comparable between treatments. CONCLUSIONS: Parecoxib is as effective as ketoprofen in the treatment of pain due to acute renal colic, is well tolerated, and has a comparable safety profile.Sociedade Brasileira de Urologia2011-12-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382011000600003International braz j urol v.37 n.6 2011reponame:International Braz J Urol (Online)instname:Sociedade Brasileira de Urologia (SBU)instacron:SBU10.1590/S1677-55382011000600003info:eu-repo/semantics/openAccessGlina,SidneyDamiao,RonaldoAfif-Abdo,JoaoMaria,Carlos Francisco SantaNovoa,RaúlCairoli,Carlos Eurico DornellesWajsbrot,DaliaAraya,Gastoneng2012-02-16T00:00:00Zoai:scielo:S1677-55382011000600003Revistahttp://www.brazjurol.com.br/ONGhttps://old.scielo.br/oai/scielo-oai.php||brazjurol@brazjurol.com.br1677-61191677-5538opendoar:2012-02-16T00:00International Braz J Urol (Online) - Sociedade Brasileira de Urologia (SBU)false
dc.title.none.fl_str_mv Efficacy and safety of parecoxib in the treatment of acute renal colic: a randomized clinical trial
title Efficacy and safety of parecoxib in the treatment of acute renal colic: a randomized clinical trial
spellingShingle Efficacy and safety of parecoxib in the treatment of acute renal colic: a randomized clinical trial
Glina,Sidney
parecoxib
ketoprofen
renal colic
lithiasis
pain
analgesia
COX-2 selective
title_short Efficacy and safety of parecoxib in the treatment of acute renal colic: a randomized clinical trial
title_full Efficacy and safety of parecoxib in the treatment of acute renal colic: a randomized clinical trial
title_fullStr Efficacy and safety of parecoxib in the treatment of acute renal colic: a randomized clinical trial
title_full_unstemmed Efficacy and safety of parecoxib in the treatment of acute renal colic: a randomized clinical trial
title_sort Efficacy and safety of parecoxib in the treatment of acute renal colic: a randomized clinical trial
author Glina,Sidney
author_facet Glina,Sidney
Damiao,Ronaldo
Afif-Abdo,Joao
Maria,Carlos Francisco Santa
Novoa,Raúl
Cairoli,Carlos Eurico Dornelles
Wajsbrot,Dalia
Araya,Gaston
author_role author
author2 Damiao,Ronaldo
Afif-Abdo,Joao
Maria,Carlos Francisco Santa
Novoa,Raúl
Cairoli,Carlos Eurico Dornelles
Wajsbrot,Dalia
Araya,Gaston
author2_role author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Glina,Sidney
Damiao,Ronaldo
Afif-Abdo,Joao
Maria,Carlos Francisco Santa
Novoa,Raúl
Cairoli,Carlos Eurico Dornelles
Wajsbrot,Dalia
Araya,Gaston
dc.subject.por.fl_str_mv parecoxib
ketoprofen
renal colic
lithiasis
pain
analgesia
COX-2 selective
topic parecoxib
ketoprofen
renal colic
lithiasis
pain
analgesia
COX-2 selective
description PURPOSE: Although nonselective nonsteroidal anti-inflammatory drugs (nsNSAIDs) and opioids are effective treatments for acute renal colic, they are associated with adverse events (AEs). As cyclooxygenase-2 selective NSAIDs may provide a safer alternative, we compared the efficacy and safety of parecoxib versus an nsNSAID in subjects with acute renal colic. MATERIALS AND METHODS: Phase IV., multicenter, double-blind, noninferiority, active-controlled study: 338 subjects with acute renal colic were randomized to parecoxib 40 mg i.v. plus placebo (n = 174) or ketoprofen 100 mg IV plus placebo (n = 164). 338 subjects with acute renal colic were randomized to parecoxib 40 mg IV (n = 174) or ketoprofen 100 mg IV(n = 164) plus placebo. Subjects were evaluated 15, 30, 45, 60, 90 and 120 minutes after treatment start and 24 hours after discharge. Primary endpoint was the mean pain intensity difference (PID) at 30 minutes by visual analog scale (VAS) (per-protocol population). An ANCOVA model was used with treatment group, country, and baseline score as covariates. Non-inferiority of parecoxib to ketoprofen was declared if the lower bound of the 95% confidence interval (CI) for the difference between the two groups excluded the pre-established margin of 10 mm for the primary endpoint. RESULTS: Baseline demographics were similar. The mean (SD) mPID30 min was 33.84 (24.61) and 35.16 (26.01) for parecoxib and ketoprofen, respectively. For treatment difference (parecoxib-ketoprofen) the lower bound of the 95% CI was 6.53. The mean change from baseline in VAS 30 minutes after study medication was ~43 mm; AEs were comparable between treatments. CONCLUSIONS: Parecoxib is as effective as ketoprofen in the treatment of pain due to acute renal colic, is well tolerated, and has a comparable safety profile.
publishDate 2011
dc.date.none.fl_str_mv 2011-12-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382011000600003
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382011000600003
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/S1677-55382011000600003
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Sociedade Brasileira de Urologia
publisher.none.fl_str_mv Sociedade Brasileira de Urologia
dc.source.none.fl_str_mv International braz j urol v.37 n.6 2011
reponame:International Braz J Urol (Online)
instname:Sociedade Brasileira de Urologia (SBU)
instacron:SBU
instname_str Sociedade Brasileira de Urologia (SBU)
instacron_str SBU
institution SBU
reponame_str International Braz J Urol (Online)
collection International Braz J Urol (Online)
repository.name.fl_str_mv International Braz J Urol (Online) - Sociedade Brasileira de Urologia (SBU)
repository.mail.fl_str_mv ||brazjurol@brazjurol.com.br
_version_ 1750318072399396865